Page 23 - Cision Ab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Total sales MSEK 25 814 (28 420) Organic sales growth 0 percent (2) Operating income before amortization MSEK 1 256 (1 086) Operaing margin 4.9 percent (3.8) Items affecting comparability (IAC) MSEK –136 (–45), relating to transformation programs and the cost-savings program in the Group Earnings per share SEK 1.86 (1.61) Earnings per share, before IAC, SEK 2.11 (1.70) Net debt/EBITDA 2.1 (2.4) Cash flow from operating activities 102 percent (34) Comments from the President and CEO "A good start to the year while continuing the ­transformation journey" A RESILIENT BUSINESS The Gr...

Ericsson's Nomination Committee appointed News provided by Share this article Share this article STOCKHOLM, April 19, 2021 /PRNewswire/ -- Ericsson's (NASDAQ:ERIC) Nomination Committee for the Annual General Meeting 2022 has been appointed in accordance with the Instruction for the Nomination Committee resolved by the Annual General Meeting 2012. The Nomination Committee consists of: Johan Forssell, Investor AB; Jonas Synnergren, Cevian Capital Partners Limited; and Ronnie Leten, the Chair of the Board of Directors. Johan Forssell is the Chair of the Nomination Committee. Shareholders who w...

Calliditas strengthens its US Commercial and Medical Affairs Organization News provided by Share this article STOCKHOLM, March 8, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced the appointment of three industry veterans: Warren Brooks, PhD, as Vice President of US Medical Affairs, Teona Johnson as Head of US Marketing and David Ferraro as Head of US Sales.  Calliditas Therapeutics has bolstered its US organization with three pharmaceutical veterans as it moves towards the potential commercialization of its lead product candidate, Nefecon. "This is an...